The study assessed both the safety and efficacy of crizotinib in comparison with platinum-based chemotherapy (pemetrexed/cisplatin or pemetrexed/carboplatin) in East Asian patients with locally advanced, recurrent, or metastatic non-squamous NSCLC with occurring translocation or inversion involving ALK [79]. Here, ALK is linked to non-small cell lung carcinoma.